Wedbush Reiterates “Outperform” Rating for Vor Biopharma (NYSE:VOR)

Vor Biopharma (NYSE:VOR)‘s stock had its “outperform” rating reissued by stock analysts at Wedbush in a research note issued on Monday,RTT News reports. They currently have a $11.00 target price on the stock.

A number of other equities research analysts also recently commented on VOR. Barclays reduced their target price on Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. HC Wainwright reaffirmed a “buy” rating and issued a $17.50 target price on shares of Vor Biopharma in a research report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 target price on shares of Vor Biopharma in a research note on Friday, September 6th. Finally, Robert W. Baird reduced their price target on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $11.36.

Vor Biopharma Stock Performance

Shares of VOR stock traded up $0.22 on Monday, hitting $1.04. 2,994,330 shares of the stock traded hands, compared to its average volume of 510,652. Vor Biopharma has a twelve month low of $0.63 and a twelve month high of $3.14. The stock has a market capitalization of $71.42 million, a PE ratio of -0.63 and a beta of -0.37. The firm’s 50-day moving average price is $0.77 and its two-hundred day moving average price is $0.94.

Vor Biopharma (NYSE:VOR) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.40) earnings per share for the quarter, meeting the consensus estimate of ($0.40). On average, equities research analysts anticipate that Vor Biopharma will post -1.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VOR. Hsbc Holdings PLC lifted its stake in Vor Biopharma by 177.0% in the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after acquiring an additional 31,333 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Vor Biopharma during the 2nd quarter worth $53,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Vor Biopharma in the second quarter valued at $63,000. Rosalind Advisors Inc. acquired a new stake in Vor Biopharma in the third quarter valued at $54,000. Finally, Acadian Asset Management LLC lifted its holdings in Vor Biopharma by 51.4% during the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock worth $79,000 after buying an additional 27,597 shares during the last quarter. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.